AKRO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AKRO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Akero Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -29.02%.
The historical data trend for Akero Therapeutics's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
ROCE % | Get a 7-Day Free Trial | -44.85 | -41.21 | -46.80 | -43.82 | -33.09 |
Akero Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROCE % | Get a 7-Day Free Trial | -30.31 | -24.82 | -24.83 | -37.18 | -29.02 |
Akero Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -148.66 | / | ( ( (356.57 - 19.083) | + | (580.271 - 19.128) ) | / 2 ) | |
= | -148.66 | / | ( (337.487 | + | 561.143) | / 2 ) | |
= | -148.66 | / | 449.315 | ||||
= | -33.09 % |
Akero Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -209.412 | / | ( ( (580.271 - 19.128) | + | (912.243 - 30.259) ) | / 2 ) | |
= | -209.412 | / | ( ( 561.143 | + | 881.984 ) | / 2 ) | |
= | -209.412 | / | 721.5635 | ||||
= | -29.02 % |
(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics (NAS:AKRO) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Akero Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan Young | officer: Chief Operating Officer | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FL, SOUTH SAN FRANCISCO CA 94080 |
Andrew Cheng | director, officer: President & CEO | 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080 |
Catriona Yale | officer: Chief Development Officer | C/O AKERO THERAPEUTICS INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
William Richard White | officer: Chief Financial Officer | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Timothy Rolph | officer: Chief Scientific Officer | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
G. Walmsley Graham | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Jane Henderson | director | C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
Patrick Lamy | officer: See Remarks | AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Skorpios Trust | other: Former 10% owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Montrago Trustees Ltd | other: Former 10% owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Blue Horizon Enterprise Ltd | other: Former 10% owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Ezbon International Ltd | other: Former 10% owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Seth Loring Harrison | director | 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
Chou Judy | director | C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO CA 64080 |
From GuruFocus
By Marketwired • 08-28-2023
By Marketwired • 06-23-2023
By GuruFocus Research • 12-13-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 06-05-2023
By GuruFocus Research GuruFocus Editor • 01-06-2023
By Value_Insider Value_Insider • 11-07-2022
By PurpleRose PurpleRose • 08-04-2022
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 05-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.